ABSTRACT
The effect of Zinc (Zn) sufficiency/supplementation of the populations on the occurrence of COVID-19 and associated severe illness/mortality remains unknown. Worldwide, general recommendations for Zn sufficiency and immune-boosting for COVID-19 are in place. A time-series association study was conducted on 23 different Zn sufficiency level but socially similar European populations/countries (Population: 522.47million; experiencing up to >150 fold difference in death rates) with supposedly similar confounders and stage of the pandemic, covering the period from pre-peak-of-infections to post-peak-of-infections till flattening of the 1st wave of infections (12 March to 26 June). Comparison of these populations, consistently displayed a strong and significant correlation/covariation of populations’ Zn sufficiency/supplementation status with the COVID-19 mortality [Pearson’s r(23): 0.7893–0.6849, p-value<0.0003] and cases per million [r(23):0.8084 to 0.5658; p-value<0.005], without requiring adjustments or extra exclusion/inclusion criterion being applied elsewhere, e.g., age, age distribution, comorbidities, sex, urbanization. Among the analyzed countries, elevated 9X mortality risk was observed for populations with >92.5 % Zn sufficiency levels at all times as compared to populations with lower Zn sufficiency. The presence of a small percentage of adults/elderly with conditions/comorbidities in the populations susceptible to higher Zn intake/supplementation related pathologies (Prasad et al., JAMA.1978; 240(20):2166-2168) could be suspected for the paradoxical observation. Controlled trials or retrospective analysis of the adverse event patients’ data seem warranted for ascertaining the basis of the observation in uncertain terms for allowing the harnessing of the full protective potential of the Zn supplementation for populations.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No external funding has been received for the work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
N/A
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data are available in the manuscript/references provided.
